Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
| Condition(s) | Gastric Cancer |
|---|---|
| Status | Recruiting |
| Phase | Phase 2 |
| Study type | Interventional |
| Summary | To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer. |
| Who can participate | Inclusion Criteria: 1. Participants will be recruited voluntarily and will provide informed consent before enrollment. They are expected to demonstrate good compliance and willingness to adhere to the study protocol, including attending follow-up visits as required. 2. Inclusion criteria for participant eligibility are as follows: 1）Age between 18 and 75 years, with no gender restrictions. 2）Histopathological confirmation of locally advanced gastric or gastroesophageal junction adenocarcinoma obtained through gastric endoscopic biopsy. 3）Clinical staging consistent with T2-3N+M0 or T4aNanyM0, confirmed by imaging (CT/MRI) and endoscopic ultrasound. 4）Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 5）Expected survival of at least 12 weeks. 3.Prior to treatment initiatio |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Tang-Du Hospital |
| Locations | Xi'an, Shannxi, China |
| Start date | 2024-05-24 |
| NCT ID | NCT06475417 |
| Official listing | https://clinicaltrials.gov/study/NCT06475417 |